Hilária Saugo Faria

Hilária Saugo Faria

Auto-generated profile, based on publicly available information

Hilária Saugo Faria

Universidade Federal de Santa Maria Escola de Medicina Santa Maria Rio Grande do Sul Brazil Escola de Medicina, Universidade Federal de Santa Maria, Santa Maria, Rio Grande do Sul, Brazil

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2026
Verified
Journal Article
Open access
CPCapela Dicazeco Pascoal
Capela Dicazeco Pascoal
HFHilária Saugo Faria
Hilária Saugo Faria
AFAntonino de Jesus Francisco
Antonino de Jesus Francisco
CPClara de Andrade Pontual Peres
Clara de Andrade Pontual Peres
LTLuiz Fernando Tavares
Luiz Fernando Tavares
VMValdano Manuel
Valdano Manuel
Several clinical trials have demonstrated the non-inferiority of transcatheter aortic valve replacement compared with surgical aortic valve replacement in patients with severe aortic stenosis and low to intermediate surgical risk. However, mid-term results are still contentious. We performed this meta-analysis to compare the safety and efficacy of transcatheter vs. surgical aortic valve replacement in the mid-term in patients with aortic stenosis at low to moderate surgical risk. We searched Embase, PubMed®, and Cochrane databases for randomized clinical trials that compared transcatheter with surgical aortic valve replacement in patients with symptomatic severe aortic stenosis with a follow-up of at least four years. Outcomes of interest were all-cause mortality and disabling stroke. We included six randomized clinical trials encompassing 6,444 patients with severe aortic stenosis, of whom 3,282 (50.9%) underwent transcatheter aortic valve replacement. There was no difference in all-cause mortality (risk ratio [RR] 1.08; 95% confidence interval [CI] 0.94 - 1.25; P = 0.30) and disabling stroke (RR 0.95; 95% CI 0.75 - 1.21; P = 0.67) between groups. In the subgroup analysis, five-year mortality (RR 1.28; 95% CI 1.10 - 1.49) was higher in the transcatheter group. The new pacemaker implantation (RR 2.22; 95% CI 1.42 - 3.45) rate was higher in the transcatheter group. However, the new atrial fibrillation (RR 0.40; 95% CI 0.31 - 0.52) rate was higher in the surgical group. Mid-term mortality and disabling stroke rates in patients with severe aortic stenosis treated with either transcatheter or surgical aortic valve replacement were similar.

2 January 2025 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
HFHilária Saugo Faria
Hilária Saugo Faria
RMRian Barreto Arrais Rodrigues de Morais
Rian Barreto Arrais Rodrigues de Morais
EBElísio Bulhões
Elísio Bulhões
LBLucas Cael Azevedo Bendaham
Lucas Cael Azevedo Bendaham
OGOcílio Ribeiro Gonçalves
Ocílio Ribeiro Gonçalves
YSYafell Serulle
Yafell Serulle
The efficacy and safety of P2Y12 inhibitors (P2Y12i) with aspirin in patients with non-cardioembolic ischemic cerebrovascular events remains a topic of ongoing debate. Therefore, we conducted an updated meta-analysis to compare these drugs with aspirin alone. We systematically searched PubMed, Embase, and Cochrane Central for randomized controlled trials (RCTs) comparing the two treatment regimens in patients with ischemic cerebrovascular events. Primary outcomes were all-cause mortality, severe bleeding, and stroke recurrence. We performed subgroup analyses stratified by National Institutes of Health Stroke Scale (NIHSS). Risk ratios (RRs) with 95 % confidence intervals were calculated using a random effects model. R software (version 4.3.2) was used for statistical analyses. Fifteen studies were included, comprising 38,851 patients, of whom 19,483 (50.1 %) received P2Y12i plus aspirin. Follow-up ranged from 7 days to 3.4 years. P2Y12i plus aspirin significantly reduced stroke recurrence (RR 0.78; 95 % CI = 0.71-0.87; p < 0.05), but increased the incidence of all-cause mortality (RR 1.38; 95 % CI = 1.11-1.72; p < 0.05) and severe bleeding (RR 2.07; 95 % CI 1.61 to 2.66; p > 0.05) compared with aspirin. There was no significant difference between groups in all-cause mortality in patients with NIHSS ≤3 or ≤10. P2Y12i plus aspirin reduced stroke recurrence, but increased all-cause mortality and severe bleeding in patients with non-cardioembolic ischemic events. There was no difference between groups in all-cause mortality in patients with NIHSS scores ≤3 or ≤10.

7 August 2024 in American Journal of Therapeutics
Verified
Journal Article
Closed access
HFHilária Saugo Faria
Hilária Saugo Faria
BPBruna Pozzebon Peixoto
Bruna Pozzebon Peixoto
MSMilene Vitória Sampaio Sobral
Milene Vitória Sampaio Sobral
VRVitor Expedito Alves Ribeiro
Vitor Expedito Alves Ribeiro
ESEsther Patricia de Souza
Esther Patricia de Souza
ABAna Carulina Guimarães Belchior
Ana Carulina Guimarães Belchior

1 January 2026 in Anesthesiology Research and Practice
Verified
Journal Article
Open access
PDF file
MCMarcela da Silva Kazitani Cunha
Marcela da Silva Kazitani Cunha
HFHilária Saugo Faria
Hilária Saugo Faria
LBLucas Mendes Barbosa
Lucas Mendes Barbosa
LNLeonardo Reischoffer Do Nascimento
Leonardo Reischoffer Do Nascimento
CFCarlos Henrique de Oliveira Ferreira
Carlos Henrique de Oliveira Ferreira
CPCaio Augusto Perete
Caio Augusto Perete
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.

5 July 2025 in Brazilian Journal of Anesthesiology (English Edition)
Verified
Journal Article
Open access
LBLucas Cael Azevedo Ramos Bendaham
Lucas Cael Azevedo Ramos Bendaham
ANAltair Pereira de Melo Neto
Altair Pereira de Melo Neto
HFHilária Saugo Faria
Hilária Saugo Faria
AFAndré Richard da Silva Oliveira Filho
André Richard da Silva Oliveira Filho
CFCarlos Henrique de Oliveira Ferreira
Carlos Henrique de Oliveira Ferreira
FMFabrício Tavares Mendonça
Fabrício Tavares Mendonça
Tracheal extubation after general anesthesia may cause hemodynamic and respiratory complications, with no established strategies to prevent them. We conducted a meta-analysis to evaluate the safety and efficacy of beta-blockers in patients undergoing tracheal extubation. We searched the MEDLINE, EMBASE and CENTRAL databases for randomized controlled trials up to 2024 comparing beta-blockers to placebo in patients undergoing tracheal extubation. cough intensity; secondary: bronchospasm, bucking, hypertension. Risk Ratios (RR) with 95% Confidence Intervals (95% CI) were computed. Leave-one-out sensitivity and meta-regression analyses were performed for outcomes with high heterogeneity. We included 31 randomized studies, comprising 1,803 patients, of whom 965 received beta-blockers. The risk of moderate/severe cough (RR = 0.21; 95% CI 0.13 to 0.34; p < 0.001; I2 = 0%) and hypertension (RR = 0.28; 95% CI 0.13 to 0.58; p < 0.001; I2 = 45%) was significantly lower in the beta-blockers group compared with the placebo group. There were no statistically significant differences between groups in the risk of bronchospasm (RR = 0.58; 95% CI 0.17 to 1.94; p = 0.375; I2 = 0%) or bucking (RR = 0.47; 95% CI 0.20 to 1.13; p = 0.093; I2 = 72%). Sensitivity analysis identified Mendonça (2023) as the main heterogeneity source in bucking. Our study demonstrates that beta-blockers reduced moderate/severe cough and hypertension in patients undergoing tracheal extubation compared with placebo with no significant difference in the risk of bronchospasm and bucking. These findings suggest beta-blockers may be a valuable strategy for preventing peri-extubation hemodynamic instability and airway hyperresponsiveness. CRD42024542103.